Supernus Pharmaceuticals, Inc. - stock earnings
SUPN Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| Aug. 6, 2024 BeforeMarket | - / - | 145.1 million | - / 148.9 million | 154.3 million |
SUPN Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2024Q1 | 124000 USD | 143.6 million USD |
| 2023Q4 | 1.2 million USD | 164.3 million USD |
| 2023Q3 | -16.0 million USD | 153.9 million USD |
| 2023Q2 | -831000 USD | 135.6 million USD |
| 2023Q1 | 16.9 million USD | 153.8 million USD |
| 2022Q4 | 25.5 million USD | 167.3 million USD |
| 2022Q3 | 1.7 million USD | 177.4 million USD |
| 2022Q2 | 7.9 million USD | 170.1 million USD |
| 2022Q1 | 2.4 million USD | 159.1 million USD |
| 2021Q4 | 2.4 million USD | 159.1 million USD |
| 2021Q3 | 21.6 million USD | 148.5 million USD |
| 2021Q2 | 23.7 million USD | 141.3 million USD |
| 2021Q1 | 5.7 million USD | 130.9 million USD |
| 2020Q4 | 30.8 million USD | 143.6 million USD |
| 2020Q3 | 40.0 million USD | 155.1 million USD |
| 2020Q2 | 34.7 million USD | 126.7 million USD |
| 2020Q1 | 21.5 million USD | 95.0 million USD |
| 2019Q4 | 33.1 million USD | 100.4 million USD |
| 2019Q3 | 28.9 million USD | 102.1 million USD |
| 2019Q2 | 32.7 million USD | 104.7 million USD |
| 2019Q1 | 18.3 million USD | 85.5 million USD |
| 2018Q4 | 25.9 million USD | 115.9 million USD |
| 2018Q3 | 28.0 million USD | 103.0 million USD |
| 2018Q2 | 30.7 million USD | 99.5 million USD |
| 2018Q1 | 26.4 million USD | 90.4 million USD |
| 2017Q4 | 13.7 million USD | 88.4 million USD |
| 2017Q3 | 16.0 million USD | 80.4 million USD |
| 2017Q2 | 17.4 million USD | 75.8 million USD |
| 2017Q1 | 10.3 million USD | 57.6 million USD |
| 2016Q4 | 61.8 million USD | 56.8 million USD |
| 2016Q3 | 61.8 million USD | 56.8 million USD |
| 2016Q2 | 10.3 million USD | 50.4 million USD |
| 2016Q1 | 4.8 million USD | 43.1 million USD |
| 2015Q4 | 6.9 million USD | 42.7 million USD |
| 2015Q3 | 3.9 million USD | 38.6 million USD |
| 2015Q2 | 2.4 million USD | 35.1 million USD |
| 2015Q1 | 738000 USD | 28.1 million USD |
| 2014Q4 | 4.4 million USD | 30.8 million USD |
| 2014Q3 | 27.9 million USD | 52.5 million USD |
| 2014Q2 | 3.2 million USD | 29.7 million USD |
| 2014Q1 | -15.5 million USD | 9.1 million USD |
| 2013Q4 | -22.4 million USD | 10.3 million USD |
| 2013Q3 | -24.1 million USD | 1.3 million USD |
| 2013Q2 | -27.4 million USD | 281000 USD |
| 2013Q1 | -18.4 million USD | 147000 USD |
| 2012Q4 | -13.5 million USD | 1.1 million USD |
| 2012Q3 | -13.5 million USD | 91000 USD |
| 2012Q2 | -10.0 million USD | 91000 USD |
| 2012Q1 | -9.3 million USD | 208000 USD |
| 2011Q4 | 82.0 million USD | -9.8 million USD |
| 2011Q3 | -9.7 million USD | 11000 USD |
| 2011Q2 | -7.4 million USD | 750000 USD |
| 2011Q1 | -11.0 million USD | ? USD |
| 2010Q4 | -8.6 million USD | -8.6 million USD |
| 2009Q4 | -8.2 million USD | -5.1 million USD |
| 2008Q4 | ? USD | 8.9 million USD |
SUPN Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | 1.3 million USD | 607.5 million USD |
| 2022 | 60.7 million USD | 667.2 million USD |
| 2021 | 53.4 million USD | 579.8 million USD |
| 2020 | 127.0 million USD | 520.4 million USD |
| 2019 | 113.1 million USD | 392.8 million USD |
| 2018 | 111.0 million USD | 408.9 million USD |
| 2017 | 57.3 million USD | 302.2 million USD |
| 2016 | 91.2 million USD | 215.0 million USD |
| 2015 | 14.0 million USD | 144.4 million USD |
| 2014 | 19.9 million USD | 122.0 million USD |
| 2013 | -92.3 million USD | 12.0 million USD |
| 2012 | -46.3 million USD | 1.5 million USD |
| 2011 | 56.0 million USD | 803000 USD |
| 2010 | -38.5 million USD | 106000 USD |
| 2009 | 460000 USD | 37.9 million USD |
| 2008 | -33.5 million USD | 8.9 million USD |
| 2007 | -17.3 million USD | 4.2 million USD |
SUPN
Price: $29.10
52 week price:
Earnings Per Share: 0.02 USD
P/E Ratio: 66.45
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 524852
Ebitda: 27.4 millionMarket Capitalization: 1.6 billion